welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)The purpose of the study is to assess th...
-
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical tri...Duchenne muscular dystrophy (DMD) is an ...
-
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open...Background: Drisapersen induces exon 51...
-
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Mu...Sarepta Therapeutics, Inc., the leader i...
-
Ataluren Confirmatory Trial in DMD: Effect of Ataluren on Activities of Daily Living in Nonsense Mutation Duchenne M...Objective:Evaluate the effect of atalure...
-
The Duchenne RegistryThe Duchenne Registry is an online, pati...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
